Sildenafil Tablet, Film Coated
Product Images NDC 68071-3832

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 68071-3832). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3832 3)

Packaging label for Sildenafil 100 mg tablets by NuCare Pharmaceuticals, Inc. The label indicates a package of 30 film-coated oral tablets with product number R1789030. It includes barcode, distribution information, lot, expiration, serial numbers, storage instructions, and a child safety warning. Marked as Rx only.*

FDA Label Image

Figure 1 (Sildenafil Fig1)

A line graph comparing the mean change from baseline in sitting systolic blood pressure (mmHg) over 24 hours post dose between Sildenafil 100 mg and placebo in healthy volunteers. The x-axis shows time post dose in hours, and the y-axis shows systolic blood pressure changes. Two line plots with distinct markers represent the two groups across multiple time points.*

FDA Label Image

Figure 2 (Sildenafil Fig2)

A line graph showing the mean standing systolic blood pressure (SBP) change from baseline over an 8-hour postdose period. Two data series compare the effects of Doxazosin plus Placebo and Doxazosin plus Sildenafil 25 mg on SBP, with SBP change plotted on the vertical axis and time in hours on the horizontal axis.*

FDA Label Image

Figure 3 (Sildenafil Fig3)

A line graph comparing mean standing systolic blood pressure changes from baseline over 8 hours postdose for two treatments: Doxazosin plus placebo and Doxazosin plus Sildenafil 50 mg. The y-axis shows the change in systolic blood pressure in mmHg, and the x-axis shows time in hours after dosing.*

FDA Label Image

Figure 4 (Sildenafil Fig4)

A line graph depicting mean standing systolic blood pressure change from baseline over time after dosing up to 8 hours. It compares two groups: one receiving Doxazosin plus Sildenafil 100 mg and the other Doxazosin plus Placebo. The y-axis shows blood pressure change in mmHg, and the x-axis shows time in hours post-dose.*

FDA Label Image

Figure 5 (Sildenafil Fig5)

A line graph showing mean sildenafil plasma concentrations (ng/mL) over a 24-hour period post-dose in healthy male volunteers. The x-axis represents time post dose in hours, and the y-axis represents plasma concentrations. The graph illustrates plasma levels rising quickly after dosing, peaking around 1 hour, then gradually declining over time, showing data for a commercial sildenafil tablet.*

FDA Label Image

Figure 6. Effect Of Sildenafil And Placebo On Maintenance Of Erection By Baseline Score (Sildenafil Fig6)

Two bar graphs comparing the effect of Sildenafil and Placebo on maintenance of erection by baseline score. The x-axis shows baseline scores from 0 to 5, and the y-axis represents the percentage of patients at endpoint. Different shades represent scores from 0 to 5 in the legend. The top graph illustrates Sildenafil effects, and the bottom graph shows Placebo effects.*

FDA Label Image

Sildenafile Fig 7 (Sildenafil Fig7)

A vertical bar chart titled "Percentage of Patients Reporting Improvement in Erections", comparing the placebo group and Sildenafil treatment groups at doses of 25 mg, 50 mg, and 100 mg. The bars represent increasing percentages of patient improvement across the treatment groups, with percentages labeled above each bar (24% placebo, 63% 25 mg, 74% 50 mg, 82% 100 mg). The x-axis indicates the treatment groups, and the y-axis indicates the percentage of patients reporting improvement.*

FDA Label Image

Structure (Sildenafil Str)

Chemical structure of sildenafil showing the molecular framework with its characteristic sulfonamide, piperazine, and pyrazolo[4,3-d]pyrimidinone components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.